Mahkam Zanganeh - 08 Apr 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role: Co-Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Mahkam Zanganeh
Issuer symbol: SMMT
Transactions as of: 08 Apr 2025
Net transactions value: +$6,296,387
Form type: 4
Filing time: 09 Apr 2025, 17:19:31 UTC
Previous filing: 11 Feb 2025
Next filing: 01 May 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SMMT	Common Stock	Exercise of in-the-money or at-the-money derivative security	$6,296,387	+3,985,055	+0.72%	$1.58	555,680,151	08 Apr 2025	By Spouse	F1, F2
holding	SMMT	Common Stock						10,199,776	08 Apr 2025	By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee	F2
holding	SMMT	Common Stock						25,457,666	08 Apr 2025	By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee	F2
holding	SMMT	Common Stock						50,000	08 Apr 2025	Immediate family member	F2
holding	SMMT	Common Stock						31,000	08 Apr 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SMMT	Warrant (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	+3,985,055		$0.000000	0	08 Apr 2025	Common Stock	3,985,055	$1.58	By Spouse	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On April 8, 2025, the Reporting Person's spouse exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share
F2	The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.